Mereo wins New Overweight at J.P. Morgan ahead of trial readouts

narvikk

Mereo BioPharma (NASDAQ:MREO) traded higher on Thursday after J.P. Morgan launched its coverage with an overweight recommendation, citing two late-stage trial readouts the U.K.-based biotech is scheduled to report this year.

The readouts related to Mereo’s (NASDAQ:MREO) lead pipeline